What is it about?
Chemoprevention of cancer creates a sustainable chemical environment through vitamins, nutritional supplements, or drugs. The innovative work published in Wiley's journal Cancer of the American Cancer Society (ACS) focuses on the topic of cancer prevention. The work innovates by systematically assessing the impact of vitamin supplements or drugs to reduce risk for skin disease, aging, and cancer in particular malignant melanoma.
Featured Image
Why is it important?
Cancer patients often look back at their lives and would do anything to turn back time and cut out the major causes of cancer by limiting sunburns, poor diet, alcohol, and smoking. However, as tissues differentiate, age, and response to carcinogens, many somatic, epigenomic, immunological, and metabolic changes get manifested in the course of a life. After all, some of those changes might be reversible. What does a targeted effort need to comprise to effectively slow down or even revert such changes? To systematically battle skin cancer, a new effort on chemoprevention delivers a state-of-the-art pipeline to translate the most promising chemoprevention agents for high-risk melanoma patients into the clinic.
Perspectives
A recent community effort provides a comprehensive perspective on state of the art clinical and basic melanoma research. https://doi.org/10.1111/pcmr.12728 The authors identify emerging frontiers in clinical and basic research of melanocyte biology and its associated biomedical disciplines. We describe challenges and opportunities in clinical and basic research of normal and diseased melanocytes that impact current approaches to research in melanoma and the dermatological sciences. We focus on four themes: 1) clinical melanoma research, 2) basic melanoma research, 3) clinical dermatology, and 4) basic pigment cell research, with the goal of outlining current highlights, challenges, and frontiers associated with pigmentation and melanocyte biology. This perspective encapsulates important advances in melanocyte and melanoma research including emerging frontiers in melanoma immunotherapy, medical and surgical oncology, dermatology, vitiligo, albinism, genomics and systems biology, epidemiology, pigment biophysics and chemistry, and evolution.
Fabian Filipp
University of California Merced
Read the Original
This page is a summary of: Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials, Cancer, October 2018, Wiley,
DOI: 10.1002/cncr.31719.
You can read the full text:
Resources
Contributors
The following have contributed to this page
